Swiss village buried after glacier collapse
GENEVA, Switzerland - A large section of the mountain village of Blatten in southern Switzerland was buried under an avalanche of ice, mud and rocks after a massive glacier gave way on Wednesday.
Photos from the disaster zone showed feet of debris sliding down the mountainside, with most of the village submerged beneath the debris field.
Only a few rooftops remained visible following the collapse of the Birch Glacier, which had shown signs of instability in recent weeks.
Engineers had been monitoring the glacier and issued evacuation notices more than a week before the collapse, which prevented a greater tragedy.
According to seismologists, the force of the avalanche was equivalent to a magnitude 3.1 earthquake.
The Swiss government was closely monitoring the situation for any additional slides, which could force more additional evacuations.
Antarctica's 'Doomsday Glacier' Is Melting Away Differently Than Scientists First Thought
According to Swiss government estimates, Blatten is home to a population of only around 300 people, but that figure typically swells during the busy ski season, which runs annually from December into early April.
Emergency crews are actively monitoring the disaster zone for any missing people, but a government official said as of Wednesday evening there were no reported injuries from the event.
"It's terrible to lose your home. I feel for the residents of Blatten," Swiss President Karin Keller-Sutter said in a statement.
The Alps are home to thousands of glaciers, but many are retreating and melting, according to a recent NASA survey.
The range's largest ice sheet is known as the Great Aletsch Glacier and is located in southwestern Switzerland.
According to the Swiss Glacier Monitoring Network, the giant glacier has retreated by more than 4,300 feet since 1984.
How Scientists Believe The Loss Of Arctic Sea Ice Will Impact Us Weather Patterns
Melting glaciers and the depletion of sea ice are widely considered to be major contributors to rising sea levels and shifting climates across the globe.
NASA reports that Antarctica alone loses approximately 150 billion tons of ice each year, while melting in Greenland results in 270 billion tons of annual ice loss.Original article source: Swiss village buried after glacier collapse
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Biovica Secures Three New Work Orders in Pharma Services of 2,5 MSEK in Value
UPPSALA, SE / / June 10, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, has signed three new work orders within its Pharma Services business, with a combined value of approximately SEK 2.5 million. The agreements are for TKa testing services with existing customers. Two of the three work orders were placed by the Tier-1 (revenues >10 BUSD) U.S. pharmaceutical company which recently entered into a broader service agreement with Biovica, including a record-breaking SEK 4 million work order. These latest orders will support the development of next-generation CDK4/6 inhibitors. The orders are a combination of retrospective analysis, that will be performed in the coming months, and prospective analysis that will be performed over ~2 years. "I'm pleased to see that our Pharma customers recognize the value of DiviTum® TKa and are returning for continued use. The reliable and meaningful data it provides continues to drive demand from leading pharmaceutical companies, who use it in the development of new cancer therapies that will benefit patients.," said Anders Rylander, CEO of Biovica. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments Biovica secures three new work orders in Pharma Services of 2,5 MSEK in value SOURCE: Biovica International View the original press release on ACCESS Newswire
Yahoo
34 minutes ago
- Yahoo
FG001 clinical data in High-Grade Glioma is now published in Neurosurgery
KØBENHAVN, DK / / June 10, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company focused on precision cancer surgery, is pleased to announce its compelling phase I clinical data with FG001 has been published in Neurosurgery. The data is the first-in-human result of its proprietary near-infrared (NIR) optical imaging agent, FG001, in patients with malignant glioma undergoing surgery. The article, published in the prestigious journal Neurosurgery, which targets neurosurgeons, is entitled "Novel uPAR-targeting optical imaging agent ICG-Glu-Glu-AE105 (FG001) for visualization of malignant glioma during surgery: First-in-human study in 35 brain cancer patients" and identified with doi:10 1227/neu.0000000000003542, available here: link. "We are very pleased with the publication of the results from this first-in-human study that shows FG001 not only enables safe and targeted tumor identification including in the transition zone, being the tissue between the cancer and normal tissue which constitutesthe biggest challenge for the surgeon treating high-grade glioma - where the agent continued to produce visible fluorescence." said Morten Albrechtsen, CEO of FluoGuide; "FG001 has the potential to redefine how surgeons approach brain tumor resection" Next clinical step and regulatory pathFollowing the successful completion of this phase I study, FluoGuide is obtaining FDA regulatory advice prior to initiate the U.S. clinical trial supporting approval of FG001 guiding surgery of patients with High Grade Glioma. FluoGuide anticipates feedback from ongoing regulatory interactions over the summer. "I am pleased to see the first result of FG001 in patients with malignant glioma published" says Jane Skjøth-Rasmussen, MD, PhD, Chief Physician in the Department of Neurosurgery at Rigshospitalet, Copenhagen, Denmark and Principal Investigator of the trial and the author of the publication, and continues: "The data demonstrates FG001 to be well tolerated and shows a promise for guiding surgery of malignant glioma." In an editorial comment published together with the article Professor Pierre A. Robe, Chair of Neurosurgical Oncology at the University Medical Center (UMC) concludes: "Altogether, the results reported here are a welcome and exciting addition to the brain tumor neurosurgical community." Please refer to the published article for the full commentary. Glioblastoma is among the most aggressive and lethal forms of brain cancer, with a crucial need for tools that enable maximal tumor resection while preserving healthy brain tissue. FG001 lights up cancer, enabling surgeons to perform more precise surgeries. It is an novel imaging agent that targets the urokinase-type plasminogen activator receptor (uPAR), a protein highly expressed in tumor tissue but largely absent from normal brain cells. Key results from the phase I studyThe result is from the first clinical trial with FG001 in patients with High Grade Glioma and is an open-label, single-center phase I trial involving 35 patients, and FG001 was administered intravenously prior to brain surgery. A dose of 36 mg administered 12-19 hours before surgery provided optimal tumor visualization. The tumor-to-background fluorescence ratio (TBR) was relevant for all image system tested (>1.5) and up to 2.7 (TBR mean) and 3.6 (TBR max). Notably, FG001 achieved a sensitivity of 79% and a specificity of 100% in identifying malignant tissue confirmed by histopathology. Compared with the imaging agent 5-ALA, FG001 was observed to provide clearer delineation in deeper tissue layers due to its NIR fluorescence properties, with no observed false positives. FG001's safety profile was equally promising, with only few (4) mild drug-related adverse events linked to the drug. It was observed that unlike 5-ALA, no FG001-related nausea or vomiting was reported in patients receiving evening doses, underscoring FG001s favorable tolerability. High precision in the transition zoneThe transition zone, being the tissue between the tumor and the normal tissue, is of special attention to neurosurgeons as it is where they must make the difficult decisions between removing tissue that may be cancer and risking disabling patients by removing more brain tissue than necessary. FG001 worked well in the transition zone where all 7 samples were correctly classified by FG001 whereas 5-ALA had 2 false negative. When the efficacy was calculated for transition zone only, then specificity, sensitivity, positive predictive value (PPV), and negative predictive value (NPV) were all 100% for FG001, whereas the numbers were 100%, 60%, 100%, and 50% for 5-ALA, respectively. For further information, please contact:Morten Albrechtsen, CEOFluoGuide A/SPhone: +45 24 25 62 66E-mail: ma@ Certified Adviser:Svensk Kapitalmarknadsgransking ABWebsite: About FluoGuideFluoGuide is a biotech company specializing in precision cancer surgery improving the outcome for cancer patients. The Company's lead product, FG001, a novel optical imaging agent that light up cancerous tissue to improve surgical precision in patients undergoing surgery. FluoGuide's products are expected to have a dual benefit - reducing both the frequency of local recurrence after surgery and reducing surgical complications. The improved precision will potentially increase the patients' chance of achieving a complete cure and lower healthcare costs. FG001 binds to the urokinase plasminogen activator receptor (uPAR) being extensively expressed by solid cancer. The photosensitizer therapy potential of FG001 could add a direct treatment effect of FG001 to further benefit for patients with cancer undergoing surgery. The Company has published strong results from phase II trials demonstrating the efficacy of FG001 in patients undergoing surgery to remove aggressive brain (high-grade glioma), head & neck (oral squamous cell carcinoma) and lung cancers (non-small cell lung cancer). FG001 has also been demonstrated very well tolerated across all patients. Based on this strong foundation, FluoGuide advances the development toward approval in aggressive brain cancer and head & neck cancer. FluoGuide is listed on Nasdaq First North Growth Market, Stockholm under the ticker "FLUO". Read more about FluoGuide and upcoming events on AttachmentsFG001 clinical data in High-Grade Glioma is now published in Neurosurgery SOURCE: FluoGuide A/S View the original press release on ACCESS Newswire


Bloomberg
4 hours ago
- Bloomberg
Musk Is the $350 Billion Rocket Man Who Fell to Earth
The popcorn emoji is out in force as the world's richest person feuds with its most powerful leader. Even Thierry Breton, the European regulator who was a frequent target of Elon Musk's ire, is at it. Still, as entertaining as the billionaire's spat with Donald Trump may be, it also carries costly lessons for a $630 billion space economy dominated by Musk's Space Exploration Technologies Corp. — such is the danger of codependence between de facto monopolies and increasingly protectionist states. This danger wasn't high on the agenda at the peak of Trump's bromance with Musk, when the president-elect described SpaceX's reusable rocket revolution in the way a Renaissance monarch might have praised a successful colonial expedition — with a mix of national pride, geopolitical influence and financial potential: ' I called Elon. I said, 'Elon, was that [landing maneuver] you?' He said, 'Yes, it was.' I said, '...Can Russia do it?' 'No.' 'Can China do it?' 'No.' 'Can the United States do it, other than you?' 'No, nobody can do that.' 'That's why I love you, Elon.''